as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹515.65
Change
+4.35 (0.85%)
Open
₹511.3
Prev. Close
₹511.3
Day High
₹530.0
Day Low
₹509.45
Volume Analysis
Traded
21,290
Delivered
9,191
Delivery %
43.17%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (26.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (16.5%)
- •Strong 3-year revenue growth (16.7%)
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹547.84 | ₹538.92 | ₹527.29 | ₹518.37 | ₹506.74 | ₹497.82 | ₹486.19 |
| Fibonacci | ₹538.92 | ₹531.07 | ₹526.22 | ₹518.37 | ₹510.52 | ₹505.67 | ₹497.82 |
| Camarilla | ₹521.3 | ₹519.42 | ₹517.53 | ₹518.37 | ₹513.77 | ₹511.88 | ₹510.0 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-30.36%
1 Week
-0.46%
1 Month
+0.13%
3 Months
-8.19%
6 Months
-8.34%
1 Year
-36.96%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹474.49
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
8.2%
Net margin 11.14% × asset turnover 0.37x × equity multiplier 1.99x
Company Overview
Sector
Healthcare
Market Cap
₹1,661 Cr
P/E (TTM)
16.9
ROE
10.9%
Book Value
₹320.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Krsnaa Diagnostics Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 57/100. The strongest factor is Growth (88/100), while Momentum (13/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (26.0%). Strong 3-year EPS growth (16.5%).
TopFund Score — Fundamentals Quality
57/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Promoter holding is low: 27.1%
- −Company has a low return on equity of 9.11% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Earnings Call Transcript for quarter and half year ended September 30, 2026
KFin Technologies shifts corporate office from December 1, 2026; registered office remains unchanged.
Audio recording of Q2FY27 earnings call dated November 03, 2026 uploaded on company website.
Submitted auditor certificate confirming ICDR Regulation 169(4) compliance.
Krsnaa Diagnostics wins Delhi MCD 10-year cash PPP project for CT Scan and MRI at three hospitals.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 155 | 158 | 166 | 170 | 186 | 175 | 186 | 193 | 206 | 181 | 193 | 236 | 271 |
| Expenses + | 124 | 121 | 123 | 128 | 137 | 129 | 133 | 142 | 147 | 135 | 138 | 178 | 200 |
| Operating Profit | 32 | 37 | 44 | 43 | 49 | 45 | 53 | 51 | 59 | 46 | 55 | 58 | 71 |
| OPM % | 20.0% | 24.0% | 26.0% | 25.0% | 27.0% | 26.0% | 28.0% | 27.0% | 29.0% | 26.0% | 28.0% | 25.0% | 26.0% |
| Other Income + | 4 | 4 | 4 | 7 | 5 | 9 | 4 | 4 | 4 | 4 | 32 | 7 | 6 |
| Interest | 3 | 4 | 7 | 5 | 6 | 6 | 7 | 6 | 8 | 8 | 12 | 15 | 15 |
| Depreciation | 19 | 21 | 18 | 21 | 22 | 23 | 22 | 22 | 24 | 23 | 23 | 28 | 29 |
| Profit before tax | 13 | 16 | 23 | 23 | 25 | 25 | 29 | 27 | 32 | 20 | 52 | 22 | 33 |
| Tax % | 22.0% | 19.0% | 17.0% | 23.0% | 23.0% | 24.0% | 28.0% | 25.0% | 24.0% | 23.0% | 19.0% | 26.0% | 25.0% |
| Net Profit + | 10 | 13 | 19 | 18 | 20 | 19 | 21 | 21 | 24 | 15 | 42 | 17 | 25 |
| EPS in Rs | 3 | 4 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 5 | 13 | 5 | 8 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 26 | 34 | 25 | 22 | 20 | 10 | 12 | 13 | 11 | 4 | 4 | 22 | 32 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 39 | 61 | 455 | 487 | 620 | 717 | 773 | 880 |
| Expenses + | 30 | 42 | 324 | 365 | 475 | 527 | 561 | 650 |
| Operating Profit | 9 | 19 | 132 | 122 | 144 | 190 | 212 | 230 |
| OPM % | 23.0% | 31.0% | 29.0% | 25.0% | 23.0% | 27.0% | 27.0% | 26.0% |
| Other Income + | 3 | 2 | 15 | 19 | 17 | 26 | 43 | 49 |
| Interest | 9 | 9 | 18 | 8 | 16 | 25 | 34 | 50 |
| Depreciation | 6 | 12 | 41 | 54 | 75 | 88 | 90 | 102 |
| Profit before tax | -3 | 0 | 87 | 80 | 70 | 103 | 130 | 127 |
| Tax % | 49.0% | 180.0% | 21.0% | 23.0% | 19.0% | 24.0% | 22.0% | — |
| Net Profit + | -5 | 0 | 68 | 62 | 57 | 78 | 101 | 98 |
| EPS in Rs | -2 | 0 | 22 | 20 | 18 | 24 | 31 | 30 |
| Dividend Payout % | 0.0% | 0.0% | 11.0% | 14.0% | 14.0% | 11.0% | 6.0% | — |
| Sales growth | — | 56 | — | 7 | 27 | 16 | 8 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 6 | 6 | 669 | 723 | 794 | 867 | 964 | 1,022 |
| Borrowings + | 131 | 102 | 41 | 32 | 160 | 204 | 534 | 596 |
| Other Liabilities + | 44 | 80 | 150 | 137 | 201 | 192 | 304 | 429 |
| Total Liabilities | 186 | 192 | 875 | 908 | 1,170 | 1,278 | 1,819 | 2,064 |
| Fixed Assets + | 74 | 131 | 386 | 471 | 647 | 670 | 656 | 870 |
| CWIP | 20 | 6 | 28 | 25 | 10 | 3 | 208 | 5 |
| Investments | 1 | 1 | 0 | 0 | 0 | 32 | 57 | 57 |
| Other Assets + | 91 | 55 | 461 | 412 | 513 | 573 | 897 | 1,131 |
| Total Assets | 186 | 192 | 875 | 908 | 1,170 | 1,278 | 1,819 | 2,064 |
| Equity Capital | 5 | 5 | 16 | 16 | 16 | 16 | 16 | 16 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -23 | 64 | 128 | 76 | 24 | 87 | 143 |
| Cash from Investing Activity + | -47 | -54 | -241 | -109 | -129 | -100 | -396 |
| Cash from Financing Activity + | 105 | -41 | 176 | -33 | 84 | 14 | 279 |
| Net Cash Flow | 36 | -31 | 64 | -66 | -20 | 1 | 26 |
| Free Cash Flow | -69 | 10 | -3 | -58 | -169 | -24 | -72 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -254 | 344 | 103 | 73 | 30 | 56 | 81 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 52.94% | 54.27% | 54.23% | 53.34% | 54.27% | 54.94% | 55.25% | 54.27% | 54.86% | 55.09% | 54.08% | 54.55% |
| Promoters | 27.03% | 27.03% | 27.17% | 27.17% | 27.24% | 27.24% | 27.11% | 27.11% | 27.11% | 27.11% | 27.11% | 27.11% |
| FII | 3.44% | 3.34% | 3.33% | 3.63% | 4.04% | 3.55% | 3.4% | 3.66% | 4.17% | 3.91% | 4.28% | 3.84% |
| DII | 16.59% | 15.37% | 15.26% | 15.86% | 14.46% | 14.26% | 14.24% | 14.96% | 13.85% | 13.89% | 14.51% | 14.5% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Krsnaa Diagnostics Ltd (this stock) | 1,661 | 16.9 | 1.6 | 10.9% |
| Tarsons Products Limited | 1,678 | 205.0 | 2.65 | 2.44% |
| Fischer Medical Venture L | 1,642 | 144.0 | 3.52 | 8.91% |
| Suraksha Diagnostic Ltd | 1,780 | 42.6 | 6.45 | 14.2% |
| Ngl Fine Chem Limited | 1,783 | 27.9 | 4.92 | 17.4% |
| Bharat Parenterals Ltd. | 1,522 | 1227.0 | 4.59 | -2.54% |
| Amrutajan Health Ltd | 1,461 | 71.7 | 13.58 | 20.0% |
Which Mutual Funds Hold Krsnaa Diagnostics Ltd?
Frequently Asked Questions about Krsnaa Diagnostics Ltd
Krsnaa Diagnostics Ltd (KRSNAA) closed at ₹515.65 on NSE on 19 November 2026, up 4.35 (0.85%) from the previous close.
Krsnaa Diagnostics Ltd trades on the NSE (National Stock Exchange of India) under the symbol KRSNAA.
Krsnaa Diagnostics Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 16.9.
Krsnaa Diagnostics Ltd has a dividend yield of 0.39%.
Krsnaa Diagnostics Ltd's 52-week high is ₹835.0 and its 52-week low is ₹462.0.
Krsnaa Diagnostics Ltd has a market capitalisation of ₹1,661 crore.
Krsnaa Diagnostics Ltd has a TopFund Quality Score of 57/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Krsnaa Diagnostics Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.